Clinical trials: Enterobacteriaceae Infections
Dysentery, Shigella, Shigellosis
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children hospitalised with dysentery in Ho Chi Minh City.
- Conditions
- Dysentery, Shigella, Shigellosis, Diarrhea
- Trial name
- CIPAZ (NCT03854929)
- Testing
- Ciprofloxacin, Azithromycin
- Where
- Vietnam
- Volunteers
- 364 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Enterobacteriaceae Infections
Neonatal Acquisition of ESBL-PE in a Low-income Country - NeoLIC
Enterobacteriaceae, more specifically Escherichia coli and Klebsiella pneumoniae, are the bacteria most often responsible for neonatal infections in low-income countries.
- Trial name
- NeoLIC (NCT04836208)
- Where
- Madagascar
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Typhoid
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
This is a multicenter, randomized, observer-blinded, controlled, immune equivalence study of a multi-dose (MD) formulation with 2PE preservative of SK bioscience Vi-DT compared to single dose (SD) formulation without preservative…
- Trial name
- NCT04204096
- Testing
- Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine
- Where
- 4 sites in Philippines
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Urinary Tract Infection
The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
The SCOUT study is a multi-center, centrally randomized, double-blind, placebo-controlled non-inferiority clinical trial. 746 participants will be enrolled over a 4.5 year period.
- Trial name
- NCT01595529
- Testing
- Cefixime, Cephalexin, Trimethoprim/Sulfamethoxazole
- Where
- United States
- Volunteers
- 717 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT07286370
- Testing
- Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
- Where
- The Gambia
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid, Paratyphoid Fever
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131833
- Testing
- Typhoid Vi vaccine, Meningococcal A (control)
- Where
- China
- Volunteers
- 96,468 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Carbapenem-Resistant Enterobacteriaceae
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
The primary purpose of this clinical investigation is to establish the performance of the GenePOC Carba assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Carbapenemase…
- Trial name
- NCT03680898
- Testing
- Rectal swab collection
- Where
- 3 sites in United States, Canada
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Shigellosis
Tebipenem Trial in Children With Shigellosis
Background (brief): Shigellosis is the second leading cause of death due to diarrheal diseases worldwide (>200,000 deaths/year).
- Trial name
- NCT05121974
- Testing
- Tebipenem Pivoxil, Azithromycin, Ceftriaxon
- Where
- Bangladesh
- Volunteers
- 132 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Clinically Significant Bacteremia
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study
Main objective: to observationally assess the efficacy of different antimicrobials in Bloodstream Infection (BSI) due to Enterobacteriaceae producing ESBLs or carbapenemases.
- Trial name
- INCREMENT (NCT01764490)
- Where
- Spain
- Volunteers
- 1,344 people
- Sponsor
- JESUS RODRIGUEZ BAÑO
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related…
- Trial name
- NCT04980872
- Testing
- Miransertib
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Hemolytic-uremic Syndrome, Escherichia Coli Infections
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype.
- Trial name
- SHU O104 CUB (NCT01406288)
- Testing
- HUS standard coverage care (including in ICU)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Bordeaux
Plague
A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
This study is a randomized, open-label, non-inferiority clinical trial evaluating the safety and efficacy of oral ciprofloxacin compared to oral doxycycline for the treatment of plague in humans.
- Trial name
- NCT01243437
- Testing
- ciprofloxacin, doxyxcycline
- Where
- Uganda
- Volunteers
- 5 people
- Sponsor
- Centers for Disease Control and Prevention
Enterobacteriaceae Infections
The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan
Resistance to broad-spectrum cephalosporins through the acquisition and expression of Extended-Spectrum β-lactamase (ESBL) among Enterobacteriacea is increasing.
- Trial name
- NCT01725841
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Spinal Cord Injury, Urinary Tract Infection
Colonizing Neurogenic Bladders With Benign Flora
The purpose of the research is to determine whether we can get harmless bacteria to live in the bladders of persons with spinal cord injury who practice intermittent bladder catheterization.
- Trial name
- NCT00371631
- Testing
- Insertion of urinary catheters coated with E. coli 83972
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- US Department of Veterans Affairs
Hospital Acquired Infection
Transmission of ESBL-producing Enterobacteriaceae
The aim of this research project is to investigate the transmission of ESBL-producing Enterobacteriaceae on both, the level of bacterial strains and mobile genetic elements, and to determine the source of hospital-acquired…
- Trial name
- NCT03465683
- Testing
- ESBL-producing Enterobacteriaceae
- Where
- Switzerland
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Basel, Switzerland
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Carbapenem-Resistant Enterobacteriaceae Infection
Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly identified in children in China. Pediatric intensive care unit (PICU) is the high-risk area.
- Trial name
- NCT04535661
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Children's Hospital of Fudan University
Typhoid Fever
Typhoid Fever: Combined vs. Single Antibiotic Therapy
The current study goal is to examine the effect of Cephalosporins, Azithromycin and the combination of both on typhoid fever therapy in endemic population.
- Trial name
- NCT02224040
- Testing
- ceftriaxone, ceftriaxone and azithromycin, azithromycin
- Where
- Nepal
- Volunteers
- 120 people
- Sponsor
- Sheba Medical Center
Plague, Bubonic, Plague, Pneumonic
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
The primary objective of this trial is to test the hypothesis that ciprofloxacin monotherapy given (orally, intravenously, or combination) for 10 days is non-inferior to an aminoglycoside (given on days 1-3) followed by…
- Trial name
- IMASOY (NCT04110340)
- Testing
- Ciprofloxacin, Streptomycin, Gentamicin
- Where
- Madagascar
- Volunteers
- 222 people
- Sponsor
- University of Oxford